[go: up one dir, main page]

WO2000059893A1 - Thiopyrimidines neurotrophiques substitues - Google Patents

Thiopyrimidines neurotrophiques substitues Download PDF

Info

Publication number
WO2000059893A1
WO2000059893A1 PCT/US2000/009004 US0009004W WO0059893A1 WO 2000059893 A1 WO2000059893 A1 WO 2000059893A1 US 0009004 W US0009004 W US 0009004W WO 0059893 A1 WO0059893 A1 WO 0059893A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidine
amino
chlorophenylthio
trans
hydroxycyclohexylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/009004
Other languages
English (en)
Inventor
James L. Kelley
Thomas A. Krenitsky
Lilia M. Beauchamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Krenitsky Pharmaceuticals Inc
Original Assignee
Krenitsky Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krenitsky Pharmaceuticals Inc filed Critical Krenitsky Pharmaceuticals Inc
Priority to EP00921705A priority Critical patent/EP1165522A1/fr
Priority to AU41984/00A priority patent/AU4198400A/en
Priority to CA002369945A priority patent/CA2369945A1/fr
Publication of WO2000059893A1 publication Critical patent/WO2000059893A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Definitions

  • the present invention relates to novel derivatives of a series of substituted pyrimidines, to pharmaceutical compositions which contain them, to methods for their preparation and to their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral systems including nerve injuries.
  • Dementing disorders such as age-related cognitive disorders, e.g., senility or Alzheimer's disease are medical conditions for which there are currently only limited therapies.
  • age-related cognitive disorders e.g., senility or Alzheimer's disease are medical conditions for which there are currently only limited therapies.
  • studies suggest that multiple neurotransmitter systems are involved in senile dementia, a loss of cholinergic neurons and a severe depletion of choline acetyltransferase appear to show the earliest and strongest correlations with functional cognitive impairment [see P.T. Francis et al., Neurochemical Studies of Early-onset Alzheimer's Disease. N. Engl. J. Med., 313, 7 (1985); R.T. Bartus et al., The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions. Ann. N. Y. Acad.
  • Nerve growth factor is the best characterized neurotrophic factor that is capable of inducing cell differentiation of neural cells and promoting neurite sprouting.
  • the neurotrophic protein NGF primarily affects cholinergic neurons in the central nervous system and may be necessary for their survival [see F. Hefti and P.A. Lapchak, Pharmacology of Nerve Growth Factor in the Brain. Adv. Pharmacol., 24, 239 (1993)].
  • NGF is not systemically bioavailable, but if it is injected or infused directly into brain, it prevents neuronal cell loss and restores cognitive function in aged or lesioned rats or monkeys [see W. Fischer et al., NGF Improves Spatial Memory in Aged Rodents as a Function of Age. J.
  • NGF neurotrophic or "nerve growth factor-like”
  • AIT-082 (4[[3-(1 ,6-dihydro-6-oxo-9-purin-9-yl)-1-oxopropyl]amino]benzoic acid) is reported to enhance NGF action in cultured PC-12 cells and to restore age- induced working memory deficits in mice [see P.J.. Middlemiss et al., AIT- 082, A Unique Purine Derivative, Enhances Nerve Growth Factor Mediated Neurite Outgrowth from PC-12 cells. Neuroscience Let., 199, 131 (1995)].
  • the compound SR57746A is reported to have nerve growth factor potentiating activity and is in clinical trials [see Fournier J, et al.
  • R T is NHR4, wherein R4 is C6-10 aryl, C2-10alkyl, (C1-6alkyl)j(C3- 9cycloalkyl)(CH2)q or (C1 -6alkyl)j(C6-10aryl)(CH2)q, wherein j is 0-2 and q is 0-6, or (C1-6alkyl)j(C4-
  • heterocycloalkyl (CH2)q wherein j is 0-2, q is 0-6 and the heterocyclic ring contains one or more heteroatoms which may be the same or different and are O, S, N or NR' (wherein R' is hydrogen, C1-6 alkyl, hydroxyC2-6 alkyl, mercaptoC2- ⁇ alkyl, C1 -6alkyloxyC2-6alkyl, C1 -6alkylthioC2-6alkyl, C6-
  • Ri is piperazino or homopiperazino wherein the 4-N is substituted with a carbonylR ⁇ or sulfonylR ⁇ , wherein R5 is
  • q is 0-6 and the heterocyclic ring contains one or more heteroatoms which may be the same or different and are O,
  • R' is hydrogen, C1 -6alkyl, hydroxyC2-
  • C1-7alkylsulfonyl or C6-10arylsulfonyl and wherein C atoms of R4 and R5 may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, halogen, thiol, oxo, thioxo, carboxy, carboxamide,
  • R 2 is H or NH2;
  • R 3 is H;
  • X is a C6-10 aryl ring optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl,
  • esters or pharmaceutically acceptable esters, amides, esters, amides, salts or solvates thereof.
  • the present invention includes all enantiomeric and diastereomeric forms of the compounds of Formula I either individually or admixed in any proportion.
  • the present invention further includes prodrugs and active metabolites of the compounds of Formula I.
  • a prodrug includes any compound which, when administered to a mammal, is converted in whole or in part to a compound of Formula I.
  • An active metabolite is a physiologically active compound which results from the metabolism of a compound of Formula I, or a prodrug thereof, when such compound or prodrug is administered to a mammal.
  • the compounds of Formula I above and their pharmaceutically acceptable esters, amides, salts or solvates are sometimes hereinafter referred to as "the compounds according to the invention".
  • alkyl is meant straight or branched chain alkyl.
  • the alkyl groups may be optionally substituted with hydroxy, amino or halogen.
  • aryl is meant an aromatic ring such as phenyl or naphthyl.
  • the aryl groups may be optionally substituted with hydroxy, amino or halogen.
  • heteroaryl is meant a ring containing 1 to 4 heteroatoms selected from the group consisting of N, O and S.
  • halogen is meant F, Cl, Br or I.
  • Preferred compounds of Formula I are those wherein X is substituted phenyl; and pharmaceutically acceptable esters, amides, salts or solvates thereof.
  • Ri is C1- 10alkylcarbonylpiperizino, hydroxyC3-9cycloalkylamino, or hydroxyC6- 10arylamino
  • X is substituted phenyl, and pharmaceutically acceptable esters, amides, salts or solvates thereof.
  • R-i is 4- acetylpiperazino, 4-oxocyclohexylamino, trans-4-hydroxycyclohexylamino, 4-hydroxyanilino, or 4-(2-hydroxyethylamino);
  • X is phenyl optionally substituted with 4-chloro, 2,4 dichloro, 4- bromo, 2-fluoro-4-chloro, 2- chloro-4-fluoro, 2-methyl-4-chloro, 4-methyl, or 4-ethyl; and R 2 is NH2; and pharmaceutically acceptable esters, amides, salts or solvates thereof.
  • Specifically preferred compounds of Formula I are:
  • esters, amides, salts or solvates thereof are included in the composition.
  • amides, salts or solvates thereof are included in the composition.
  • the compounds according to the invention for use in medical therapy, particularly for the treatment of neurodegenerative or neurological disorders of the central or peripheral nervous systems.
  • nervous system disorders which may be treated in accordance with the invention include dementing disorders such as age- related senility, senile dementia or Age Related Mental Impairment (ARMI), cerebral ataxia, Parkinson's disease, Alzheimer's disease, peripheral neuropathy, cognitive disorders secondary to stroke or trauma and attention-deficit hyperactivity disorder.
  • ARMI Age Related Mental Impairment
  • cerebral ataxia Parkinson's disease
  • Alzheimer's disease peripheral neuropathy
  • cognitive disorders secondary to stroke or trauma attention-deficit hyperactivity disorder
  • nerve injuries for example, spinal cord injuries, that require neuroregeneration may also be treated in accordance with the invention.
  • spinal cord injuries that require neuroregeneration may also be treated in accordance with the invention.
  • a method for the treatment of neurodegenerative or neurological disorders of the central or peripheral nervous systems which comprises treating the subject e.g., a mammal, such as a human, with a therapeutically effective amount of a compound according to the invention.
  • Examples of pharmaceutically acceptable salts of the compounds according to the invention include acid addition salts.
  • salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compounds of the invention.
  • Preferred salts include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic, ethansulfonic, p-toluenesulfonic, benzenesulfonic and isethionic acids.
  • the compounds according to the invention and pharmaceutically acceptable esters, amides, salts or solvates thereof may be employed in combination with other therapeutic agents for the treatment of the above disorders.
  • further therapeutic agents include Cognex, Ahcept and other agents (e.g., acetylcholine esterase inhibitors, muscarinic or nicotinic receptor agonists, MAO inhibitors) that are effective for the treatment of neurodegenerative or neurological disorders of the central or peripheral nervous systems.
  • the component compounds of such combination therapy may be administered simultaneously in either separate or combined formulations, or at different times, e.g., sequentially such that a combined effect is achieved. While it is possible for compounds according to the invention to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation.
  • the formulations of the present invention comprise a compound of Formula I, as above defined, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic ingredients.
  • the carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, transdermal, intradermal, intramuscular and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon, for example, the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well know in the art of pharmacy. All methods include the step of bringing into association a compound of Formula I or a pharmaceutically acceptable salt thereof (active ingredient) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non- aqueous liquid; or as an oil-in-water liquid emulsion, or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • Formulations for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze- dried (lyophillised) condition requiring only the addition of the sterile liquid carrier, for example, water-for-injection, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1 % to 35%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis, as generally described in Pharmaceutical. Res., 3(6), 318 (1986). Formulations for rectal administration may be presented as suppository with the usual carriers such as cocoa butter or polyethylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • Tablets or other forms of presentation in discrete units may conveniently contain an amount of compound of the Formula I which is effective for each of the above-mentioned indications at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually between 10 mg to 250 mg.
  • the compounds of the Formula I are preferably administered orally or by injection (intraparenteral or subcutaneous).
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician.
  • the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration is likely to vary depending on the condition and its severity.
  • the compounds of the Formula I may be administered orally.
  • the dose range for adult humans is generally from about 10 to 4000 mg/day and preferably from about 100 to 1000 mg/day. It may be advantageous to administer an initial dose of 200 to 2000 mg the first day then a lower dose of 100 to 1000 mg on subsequent days.
  • the compounds according to the invention may be administered by injection at a dose of from about 1 to 2000 mg/day, and preferably from about 5 to 1000 mg/day.
  • the present invention further includes processes for the preparation of compounds of Formula I and esters, amides, salts or solvates thereof.
  • the compounds of Formula (I) and their esters, amides, salts and solvates may be prepared in accordance with the present invention by those methods hereinafter described, or in any manner known in the art for the preparation of compounds of analogous structure.
  • the compounds, esters, amides, salts and solvates of Formula (I) may be prepared by a process which comprises:
  • R 2 , R 3 and X are as hereinbefore defined and U is a leaving group, with an amine NH2R4 wherein R4 is as hereinbefore defined, or with a monosubstituted piperazine.
  • Suitable leaving groups include halogens such as chloride.
  • the reaction is carried out in an organic solvent (e.g., ethanol, propanol) at a temperature of approximately 20 C to approximately
  • the compound of Formula (II) may be isolated and purified prior to reaction with the amine or may be used in situ.
  • Formula III wherein R 2 , R 3 and X are as hereinbefore defined, by reaction with a halogenating agent (e.g., phosphorous oxychloride, phosphorous pentachloride, or a Vilsmeier reagent created using oxalyl chloride and N,N-diisopropylformamide) in a suitable organic solvent (e.g., dichloromethane, 1 ,2-dichloroethane, toluene, N,N-dimethlyformamide) at a temperature of approximately 40 C to approximately 100 C.
  • a halogenating agent e.g., phosphorous oxychloride, phosphorous pentachloride, or a Vilsmeier reagent created using oxalyl chloride and N,N-diisopropylformamide
  • a suitable organic solvent e.g., dichloromethane, 1 ,2-dichloroethane, toluene, N
  • R 2 and R 3 are as hereinbefore defined and W is a halogen atom such as bromo or chloro, by reaction with a suitable benzenethiol (e.g., 4- chlorobenzenethiol, 4-ethylbenzenethiol, 2,4-dichlorobenzenethiol) and a suitable base (e.g., potassium carbonate) in a suitable organic solvent (e.g., N,N-dimethylformamide, ethylene glycol, dimethylsulfoxide) at a temperature of 80°C to 140 °C.
  • a suitable benzenethiol e.g., 4- chlorobenzenethiol, 4-ethylbenzenethiol, 2,4-dichlorobenzenethiol
  • a suitable base e.g., potassium carbonate
  • a suitable organic solvent e.g., N,N-dimethylformamide, ethylene glycol, dimethylsulfoxide
  • Compounds of Formula (IV) can be prepared by various methods known in the art or are available from commercial sources.
  • Formula V wherein R 3 and X are as hereinbefore defined by reaction of an alkaline earth salt of Formula (V) with formamidine or guanidine in a suitable organic solvent (e.g., ethanol, methanol, 2-propanol, tert-butanol, tetrahydrofuran) at a temperature of approximately 60 C to the reflux temperature.
  • a suitable organic solvent e.g., ethanol, methanol, 2-propanol, tert-butanol, tetrahydrofuran
  • Formula VI wherein X is as hereinbefore defined by reaction with an ester (e.g., ethyl formate) and a strong base (e.g., sodium hydride, potassium hydride, potassium tert-butoxide, sodium metal, lithium diisopropylamide) in a suitable organic solvent (e.g., tetrahydrofuran, ether, toluene) at a temperature of approximately 0 C to approximately 40 C.
  • ester e.g., ethyl formate
  • a strong base e.g., sodium hydride, potassium hydride, potassium tert-butoxide, sodium metal, lithium diisopropylamide
  • a suitable organic solvent e.g., tetrahydrofuran, ether, toluene
  • esters and amides of compounds of Formula I can be made by reaction with a carbonylating agent (e.g., ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride) and a suitable base (e.g., 4- dimethylaminopyridine, pyridine, triethylamine, potassium carbonate) in a suitable organic solvent (e.g., tetrahydrofuran, acetone, methanol, pyridine,
  • a carbonylating agent e.g., ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride
  • a suitable base e.g., 4- dimethylaminopyridine
  • N,N-dimethylformamide at a temperature of 0°C to 60° C.
  • Salts of the compounds of Formula I can be made from the free base form by reaction with the appropriate acid.
  • N,N-diisopropylformamide (31.0 g, 0.24 mole) and methylene chloride (550 mL) were combined in a 2 L 3-neck round bottom flask equipped with an air stirrer, dropping funnel, and reflux condenser.
  • the apparatus was flushed with argon, and oxalyl chloride (33.4 g, 0.26 mole) was placed in the dropping funnel.
  • the oxalyl chloride was added portionwise over approximately 1.5 hours to the rapidly stirred solution. Stirring was continued for about 15 minutes after completion of the addition and then 5- (4-chlorophenylthio)isocytosine (21.6g, 0.085 mole)was added through a powder funnel.
  • the pH was adjusted to 7 with 3N NaOH. A large precipitate formed in the organic phase.
  • the aqueous phase was removed and the solids in the organic phase were collected by filtration and washed with dichloromethane.
  • the crude product (1.35g) was suspended in 80 ml of ethanol, then heated to boiling, and filtered while hot. As the filtrate cooled, a cotton-like precipitate formed.
  • the solids were collected by filtration, washed with ethanol, and dried in vacuo at 110 C for 15 hours. 1.05g (42% yield) of a white solid was obtained, mp. 200 C.
  • the organic phase was washed twice with 450 ml of water then with 200 ml of brine and dried over Na 2 S0 4 . After filtration, the dried organic phase was applied to a Silica Gel (230-400 mesh) column (4 x 6 cm). The product was eluted with ethyl acetate and spin evaporated at 60 C in vacuo. The resulting material was redissolved in 5 ml of hot ethyl acetate. Upon the addition of hexanes, a solid formed. The solvents were removed by decanting and the solids were suspended in 40 ml of diethyl ether and boiled with stirring. The solids were collected by filtration, washed with hexanes, and dried in vacuo at 105° C. 300 mg (10% yield) of white powder was obtained, mp 140-141 C.
  • Example A Tablet Composition m ⁇ /tablet
  • composition is prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.
  • a capsule composition is prepared by admixing the ingredients and filling into a two-part hard gelatin capsule. m ⁇ /capsule
  • Example C Injectable Composition
  • the active ingredient is dissolved in most of the water (35 - 40 C) and the pH is adjusted to between 4.0 and 7.0.
  • the batch is then made up to volume with sterile water and filtered through a sterile micropore filter into a sterile amber glass vial (type 1) and sealed with sterile closures and overseals.
  • the compounds of the invention were assayed for neurotrophic activity as follows:
  • PC12 cells rat adrenal pheochromocytoma from ATCC have receptors for NGF. Responses include promotion of neurite outgrowth and elevation of choline acetyltransferase(ChAT) (L.A. Greene and A.S. Tischler, Cell Neurobiol., 3, 373 (1982)).
  • ChAT choline acetyltransferase
  • PC12 cells were cultured at 37° C in RPMI supplemented with HEPES buffer, pH7.5 (to 10 mM), fetal bovine serum, horse serum, glutamine, penicillin, streptomycin and non- essential amino acids. Cultures were split 1 :3 every 3 to 4 days. Exponentially dividing cells were plated into fresh medium on collagen-
  • the medium was replaced with low serum medium, with or without test compounds with each condition in triplicate.
  • the medium may contain up to 0.2 % ethanol, which was used as a solvent for most compounds tested.
  • Cells were examined for morphological changes using an Olympus IMT-2 inverted research microscope. After 3 days incubation with test compounds, medium was removed and replaced with 0.2 ml of lysis and
  • ChAT assay mixture The plates were incubated at 37° C for 2 hours and then placed into a freezer at -20 C.
  • Compounds are judged NGF-like in this primary screen if they (1) increase the activity of ChAT, (2) enhance NGF-stimulated neurite outgrowth or (3) potentiate or appear additive with the action of NGF itself.
  • the assay mixture contained 100 mM phosphate, pH7.4, 0.1% NP-40, 150 mM NaCI, 1.5 mM choline, 10 mM EDTA, 0.1 mM eserine, 0.1 mM acetyl- coenzyme A and about 0.5 uCi (40-70 Ci/mol) [14C]acetyl-coenzyme A in each ml of mixture.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une série de thiopyrimidines substitués, des compositions pharmaceutiques les contenant, des méthodes concernant leur préparation et leur utilisation dans des traitements, notamment dans le traitement d'affections neurodégénérative ou autres troubles neurologiques des systèmes central et périphérique.
PCT/US2000/009004 1999-04-06 2000-04-05 Thiopyrimidines neurotrophiques substitues Ceased WO2000059893A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00921705A EP1165522A1 (fr) 1999-04-06 2000-04-05 Thiopyrimidines neurotrophiques substitues
AU41984/00A AU4198400A (en) 1999-04-06 2000-04-05 Neurotrophic thio substituted pyrimidines
CA002369945A CA2369945A1 (fr) 1999-04-06 2000-04-05 Thiopyrimidines neurotrophiques substitues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12792399P 1999-04-06 1999-04-06
US60/127,923 1999-04-06
US12884299P 1999-04-12 1999-04-12
US60/128,842 1999-04-12

Publications (1)

Publication Number Publication Date
WO2000059893A1 true WO2000059893A1 (fr) 2000-10-12

Family

ID=26826090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009004 Ceased WO2000059893A1 (fr) 1999-04-06 2000-04-05 Thiopyrimidines neurotrophiques substitues

Country Status (4)

Country Link
EP (1) EP1165522A1 (fr)
AU (1) AU4198400A (fr)
CA (1) CA2369945A1 (fr)
WO (1) WO2000059893A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800652B2 (en) 2002-08-16 2004-10-05 Pfizer Inc. Diaryl compounds
US7067665B2 (en) * 2000-12-23 2006-06-27 Sanofi-Aventis Deutschland Gmbh Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla
US7329672B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7452879B2 (en) 2003-07-30 2008-11-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
WO2011080444A1 (fr) 2009-12-14 2011-07-07 Sanofi-Aventis NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
WO2011080445A1 (fr) 2009-12-14 2011-07-07 Sanofi-Aventis NOUVEAUX DERIVES (HETEROCYCLE-TETRAHYDRO-PYRIDINE)-(PIPERAZINYL)-1-ALCANONE ET (HETEROCYCLE-DIHYDRO-PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
US8193190B2 (en) 2008-06-13 2012-06-05 Sanofi-Aventis Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
US8247404B2 (en) 2008-06-13 2012-08-21 Sanofi Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
US9763940B2 (en) 2011-12-20 2017-09-19 Sanofi Therapeutic use of P75 receptor antagonists
WO2017160569A1 (fr) 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines et variantes de celles-ci, et leurs utilisations
WO2017165255A1 (fr) * 2016-03-25 2017-09-28 Afferent Pharmaceuticals Inc. Pyrimidines et variants de celles-ci, et leurs utilisations
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
US10077276B2 (en) 2014-01-17 2018-09-18 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10758538B2 (en) 2009-08-17 2020-09-01 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US12053470B2 (en) 2017-01-10 2024-08-06 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
JP2025515208A (ja) * 2022-05-09 2025-05-13 ティーワイケー メディシンズ インコーポレーテッド 多環式化合物およびその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3154551A (en) * 1959-03-17 1964-10-27 Burroughs Wellcome Co 4-piperazino-5-arylmercapto pyrimidines
EP0826674A1 (fr) * 1995-04-03 1998-03-04 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de pyrimidine efficaces en tant que medicament psychotrope et leur procede de fabrication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3154551A (en) * 1959-03-17 1964-10-27 Burroughs Wellcome Co 4-piperazino-5-arylmercapto pyrimidines
EP0826674A1 (fr) * 1995-04-03 1998-03-04 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de pyrimidine efficaces en tant que medicament psychotrope et leur procede de fabrication

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067665B2 (en) * 2000-12-23 2006-06-27 Sanofi-Aventis Deutschland Gmbh Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329671B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7332484B2 (en) 2002-02-01 2008-02-19 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7435814B2 (en) 2002-02-01 2008-10-14 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7485724B2 (en) 2002-02-01 2009-02-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7498435B2 (en) 2002-02-01 2009-03-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7550460B2 (en) 2002-02-01 2009-06-23 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329672B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7589200B2 (en) 2002-02-01 2009-09-15 Rigel Pharmaceuticals, Inc. 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds
US7642351B2 (en) 2002-02-01 2010-01-05 Rogel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7825116B2 (en) 2002-07-29 2010-11-02 Rigel Pharmaceuticals, Inc. N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
US6800652B2 (en) 2002-08-16 2004-10-05 Pfizer Inc. Diaryl compounds
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7452879B2 (en) 2003-07-30 2008-11-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US9751893B2 (en) 2003-07-30 2017-09-05 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7560466B2 (en) 2003-07-30 2009-07-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US8193190B2 (en) 2008-06-13 2012-06-05 Sanofi-Aventis Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
US8519143B2 (en) 2008-06-13 2013-08-27 Sanofi Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
US8247404B2 (en) 2008-06-13 2012-08-21 Sanofi Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
US10758538B2 (en) 2009-08-17 2020-09-01 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US8906924B2 (en) 2009-12-14 2014-12-09 Sanofi (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
US8580790B2 (en) 2009-12-14 2013-11-12 Sanofi (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
WO2011080445A1 (fr) 2009-12-14 2011-07-07 Sanofi-Aventis NOUVEAUX DERIVES (HETEROCYCLE-TETRAHYDRO-PYRIDINE)-(PIPERAZINYL)-1-ALCANONE ET (HETEROCYCLE-DIHYDRO-PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
US8518947B2 (en) 2009-12-14 2013-08-27 Sanofi (Heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
WO2011080444A1 (fr) 2009-12-14 2011-07-07 Sanofi-Aventis NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
US8957211B2 (en) 2009-12-14 2015-02-17 Sanofi (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
US9763940B2 (en) 2011-12-20 2017-09-19 Sanofi Therapeutic use of P75 receptor antagonists
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US10077276B2 (en) 2014-01-17 2018-09-18 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US11401259B2 (en) 2014-01-17 2022-08-02 Novartis Ag 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US11952386B2 (en) 2014-01-17 2024-04-09 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10301278B2 (en) 2014-01-17 2019-05-28 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
US10336774B2 (en) 2014-01-17 2019-07-02 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10968235B2 (en) 2014-01-17 2021-04-06 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10774065B2 (en) 2014-01-17 2020-09-15 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US12209098B2 (en) 2014-01-17 2025-01-28 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
RU2761439C2 (ru) * 2016-03-14 2021-12-08 Эфферент Фармасьютикалз Инк. Пиримидины, их варианты и применение
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
WO2017160569A1 (fr) 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines et variantes de celles-ci, et leurs utilisations
CN108834412B (zh) * 2016-03-14 2022-11-25 传入制药公司 嘧啶及其变体、及其用途
EP3430000A4 (fr) * 2016-03-14 2019-12-04 Afferent Pharmaceuticals Inc. Pyrimidines et variantes de celles-ci, et leurs utilisations
JP2019508445A (ja) * 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
RU2760733C2 (ru) * 2016-03-25 2021-11-30 Эфферент Фармасьютикалз Инк. Пиримидины и их варианты, и их применение
US11230532B2 (en) 2016-03-25 2022-01-25 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN108779119B (zh) * 2016-03-25 2022-02-08 传入制药公司 嘧啶及其变体、及其用途
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
US10662162B2 (en) * 2016-03-25 2020-05-26 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
WO2017165255A1 (fr) * 2016-03-25 2017-09-28 Afferent Pharmaceuticals Inc. Pyrimidines et variants de celles-ci, et leurs utilisations
US11905283B2 (en) 2016-06-14 2024-02-20 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US12053470B2 (en) 2017-01-10 2024-08-06 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
JP2025515208A (ja) * 2022-05-09 2025-05-13 ティーワイケー メディシンズ インコーポレーテッド 多環式化合物およびその使用

Also Published As

Publication number Publication date
EP1165522A1 (fr) 2002-01-02
CA2369945A1 (fr) 2000-10-12
AU4198400A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
WO2000059893A1 (fr) Thiopyrimidines neurotrophiques substitues
CA2416442C (fr) 5-alkynyle pyrimidines substituees avec activite neurotrophique
EP1165523B1 (fr) Pyrimidines substituees neurotrophiques
US6440965B1 (en) Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
CA2004747C (fr) Composes pharmaceutiques ayant une action sur le snc
EP0781766B1 (fr) Derive heterocyclique et medicament
EP0459819B1 (fr) Composé pharmaceutiquement actif sur le SNC
US5589477A (en) Pyrimidine derivatives and drugs
EP0799617A2 (fr) Agent thérapeutique pour le traitement des maladies neurologiques
WO2004026881A1 (fr) Pyrimidines macrocycliques, leur production et leur utilisation comme medicament
AU2006304187B2 (en) Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist
KR20110002465A (ko) 세포 보호 작용을 갖는 피리미딘 유도체 및 그 용도
EP1187815B1 (fr) Derives de 4-phenyle-pyrimidine
US20100184780A1 (en) Inhibitors of protein kinases
US5358945A (en) Pyrimidine compound and pharmaceutically acceptable salts thereof
EP2137164B1 (fr) Inhibiteurs des protéines kinases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000921705

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2369945

Country of ref document: CA

Ref country code: CA

Ref document number: 2369945

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000921705

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09958265

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000921705

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP